Naldemedine
Opioid-induced Constipation
BioDelivery Sciences InternationalSmall moleculePhase 3Active
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 66/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Opioid-induced Constipation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Methylnaltrexone Bausch Health Americas, Inc. | Phase 3 | B |
Prucalopride Shire | Phase 3 | B |
Linaclotide Forest Laboratories | Phase 2 | B |
MORPHINAN-3,6,14-TRIOL, 4,5-EPOXY-17-(2-PROPENYL)-, (5.ALPHA.,6.BETA.)- S.L.A. Pharma AG | Phase 2 | B |
Lactobacillus Gasseri Bgp345A BioGaia Pharma AB | Phase 2 | B |
View all 10 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →